Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis.
April M JorgeNa LuHyon ChoiJohn M EsdaileDiane LacailleJuan Antonio Aviña-ZubietaPublished in: Arthritis care & research (2021)
In this nested case-control study of patents with SLE and RA, we found a reduced risk of overall CV events associated with current HCQ use including reductions in VTE and trends towards reductions in MI and stroke. These findings suggest a possible cardiovascular preventative benefit of HCQ use.
Keyphrases
- cardiovascular events
- rheumatoid arthritis
- disease activity
- systemic lupus erythematosus
- coronary artery disease
- venous thromboembolism
- ankylosing spondylitis
- cardiovascular disease
- atrial fibrillation
- interstitial lung disease
- type diabetes
- systemic sclerosis
- cerebral ischemia
- brain injury
- subarachnoid hemorrhage